Aitia

Discovering the next generation of breakthrough drugs

Contact for Pricing

Description

Aitia aims to be a leading AI-driven biotechnology company focused on accelerating the discovery and development of life-saving therapeutics. The company leverages the power of causal AI and multi-omic patient data to build its proprietary Gemini Digital Twins. These digital twins are designed to reveal the hidden biological mechanisms of diseases, thereby facilitating the identification of novel drug targets.

The core of Aitia's approach lies in disrupting traditional drug discovery processes through its advanced AI capabilities. By creating detailed digital representations of human diseases, Aitia works on developing a pipeline of first-in-kind programs, particularly focusing on oncology and neurodegenerative diseases. They collaborate with industry leaders through strategic partnerships to advance these discoveries.

Key Features

Causal AI: Utilized to uncover hidden biological mechanisms of diseases.
Multi-omic Patient Data Analysis: Integrates diverse biological data sets for comprehensive insights.
Gemini Digital Twins: Creates digital representations of human diseases for research and discovery.
AI-Driven Drug Pipeline: Develops novel programs targeting complex diseases.
Focus on Oncology and Neurodegenerative Diseases: Specializes in areas with significant unmet medical needs.
Strategic Partnerships: Collaborates with industry leaders to advance drug discovery.